This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice.
Study Type
OBSERVATIONAL
Enrollment
732
brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
Unnamed facility
Seoul, South Korea
Percentage of Participants Reporting Adverse Events
An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
Time frame: Up to 2.6 Years
Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. The study doctor classified the overall improvement of the IOP change from Baseline into 3 categories: Improvement (effective), No Change or Exacerbation (ineffective). The percentage of participants with Improvement is reported.
Time frame: Baseline, Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.